Evaluation of the Glucoregulatory Effects of GLP-1 Receptor Activation in Patients with Type 2 Diabetes Mellitus

Evaluation of the Glucoregulatory Effects of GLP-1 Receptor Activation in Patients with Type 2 Diabetes Mellitus - Glucose-dependent insulin secretion in type II diabetes mellitus

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35750

Enrollment

Registered

2011-05-20

Start date

2011-05-23

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes insulin secretion

Interventions

Insulin infusion Oxyntomodulin infusion Liraglutide injection

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male, 18-65 years, inclusive BMI is less than or equal to 38.0 kg/m2 Type 2 Diabetes Mellitus Patient

Exclusion criteria

Exclusion criteria: Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study or in case of donating more than 1.5 liter of blood in the 10 months prior the start of this study.

Design outcomes

Primary

Measure	Time frame
Pharmacodynamics Pharmacokinetics Safety	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)